Indication CINRYZE® (C1 esterase inhibitor [human]) is an injectable prescription medicine that is used to help prevent
swelling and/or painful attacks in teenagers and adults with Hereditary Angioedema (HAE).
Dariela, a real HAE patient,
helps prevent her
attacks with CINRYZE
Because hereditary angioedema (HAE) is rare and under-recognized, HAE symptoms are frequently misdiagnosed as other, more common conditions. If someone else in your family has been diagnosed with HAE, however, it may be easier for you to receive an accurate diagnosis sooner.
In a survey of 313 patients, 65% of participants reported receiving a misdiagnosis before being accurately diagnosed with HAE.
If your doctor suspects HAE, laboratory testing to measure your levels of C4 and C1 esterase inhibitor will likely be the next step. These tests will confirm whether you have Type I or Type II HAE.
Watch Andrea's story
It’s important to work closely with your doctor when creating a treatment plan that’s right for you. Ask your doctor about different treatment options, including preventative and on-demand therapy.
Preventative treatment is also sometimes referred to as prophylactic therapy and involves taking medicine routinely to help prevent or reduce the frequency and severity of HAE attacks.
When talking with your doctor about whether preventative therapy is an option for you, you might discuss how frequently you experience attacks and how severely they affect you. Your doctor will likely also ask about any other health conditions you might have and if you’ve tried any other methods for coping with or treating your HAE symptoms in the past.
It starts by talking with your doctor. Filling out this Doctor
Discussion Guide can help you prepare for your conversation.
Create your discussion guide
Because everyone with HAE is at risk for a throat attack, which can become life threatening because of the potential for suffocation, treatment experts also recommend keeping an on-demand treatment on hand for HAE attacks. Click here to learn about one option to treat HAE attacks in adults.
You might also be interested in:
ExpandClose Important Safety Information
You should not use CINRYZE if you have had life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product.
Tell your healthcare provider about all of your medical conditions, including if you: have an indwelling catheter/access device in one of your veins; have a history of blood clots, heart disease, or stroke; or are taking birth control pills or androgens. Also tell your healthcare provider if you are pregnant or planning to become pregnant, or are breastfeeding or planning to breastfeed. It is not known if CINRYZE can harm your unborn baby, or if CINRYZE passes into your milk and if it can harm your baby.
Allergic reactions may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, turning blue (look at lips and gums), fast heartbeat, swelling of the face, faintness, rash, hives.
Serious blood clots may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms: pain and/or swelling of an arm or leg with warmth over the affected area, discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid heart rate, numbness or weakness on one side of the body.
Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
The most common side effects seen with CINRYZE were headache, nausea, rash, and vomiting. These are not all the possible side effects of CINRYZE. Tell your healthcare provider about any side effect that bothers you or that does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see the Full Prescribing Information.
© 2017 Shire. All rights reserved. CINRYZE, OnePath, PATH TO INDEPENDENCE, and the associated logos are either registered trademarks or trademarks of Shire or its affiliates.
Mix2Vial is a registered trademark of Medimop Medical Projects, Ltd. in the United States and other jurisdictions.
This site is intended for U.S. residents and is governed by U.S. law and governmental regulations. Please see our online Privacy Policy for more information.
S10685 08/2016
